# Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

> **NCT01982682** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 41 (actual)

## Conditions studied

- Hematopoietic/Lymphoid Cancer

## Interventions

- **RADIATION:** Total-Body Irradiation (TBI)
- **BIOLOGICAL:** Donor Lymphocyte Infusion (DLI)
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplantation (HSCT)
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT01982682
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-04
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-03-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01982682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01982682, "Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01982682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*